COPENHAGEN (Reuters) – Novo Nordisk will begin a Phase II trial of its highly anticipated experimental drug amycretin in the second half of the year with results due in early 2026, the company’s head of research and development Martin Lange Holst said on Thursday.
(Reporting by Jacob Gronholt-Pedersen, editing by Terje Solsvik)
Comments